Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission (EC) to convert…
-
-
HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
-
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
-
Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
-
Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
-
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
-
Biotechnology | CRISPR | Disease | Genomics | Therapeutics
U.S. patent appeal board ruled against University of California in CRISPR interference
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
-
EMA’s Committee for Medicinal Products for Human Use recommended authorization of Covid-19 vaccine in children (6-11 Years) In the EU
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
Moderna expanded global footprint through commercial partnership with Adium in Latin America
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
-
Therapeutic Goods Administration of Australia authorized Moderna’s Covid-19 vaccine in children (6-11 Years)
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
-
Moderna announced new supply agreement with Colombia for additional 10.8 million doses of COVID-19 vaccine
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
-
CDC’s ACIP issued recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
-
Moderna received full U.S. FDA approval for COVID-19 vaccine Spikevax
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA) had approved the Biologics License…
-
Moderna announced first participant dosed in phase 2 study of Omicron-specific booster candidate and publication of data
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
-
Moderna announced Switzerland exercised option to purchase seven million additional doses of COVID-19 booster vaccine
On Dec. 27, 2021, Moderna announced that the Swiss Federal Government had exercised its option to purchase an…
-
Moderna announced supply agreement with South Korea for additional 20 million doses of COVID-19 vaccine
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
-
Moderna announced preliminary booster data and updated strategy to address Omicron variant
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…
-
Moderna and Australia announced collaboration to bring mRNA manufacturing to Australia
On Dec. 13, 2021, Moderna announced an agreement with the Australian Government to build a state-of-the-art messenger RNA…
-
Moderna announced additional 20 million doses of COVID-19 vaccine to COVAX for supply in 2021 and additional supply for 2022
On Dec. 10, 2021, Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to…
-
Resilience and Harvard University announced five-year R&D alliance to incubate new technologies
On Dec. 2, 2021, National Resilience and Harvard University announed they had established a five-year research and development…
-
Moderna announced supply agreement with the UK for additional 60 million doses of COVID-19 vaccine in 2022 and 2023
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
-
FDA announced FDA authorization of Moderna’s booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
-
EU to donate more than 70 million doses of Moderna COVID-19 vaccine to COVAX to fight COVID-19 pandemic in low income countries
On Nov. 16, 2021, an agreement was announced that enabled the European Union and European Economic Area countries…
-
Health Canada authorized booster dose of Moderna’s COVID-19 vaccine in individuals 18 years of age and older
On Nov. 15, 2021, Moderna confirmed that Health Canada had authorized the use of a booster dose of…
-
Moderna filed to expand the conditional Marketing Authorization for COVID-19 vaccine in the EU to include children ages 6-11 years
On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…
-
Moderna updated timing of U.S. Emergency Use Authorization of its COVID-19 vaccine for adolescents
On Oct. 31, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had notified the Company…
-
Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccine
On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine…
-
Moderna announced MOU to supply up to 110 million doses of Its COVID-19 vaccine to the African Union
On Oct. 26, 2021, Moderna announced a new Memorandum of Understanding (MoU) to make up to 110 million…
-
Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age
On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…
-
Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
